• Germany’s projected EU tariff burden of $81.5 billion leads to potential European exposure.
• Tech and pharma in 10 EU countries face combined $271.2 billion in potential tariffs

As the July 9 deadline approaches for renewed US-EU trade negotiations, Germany’s potential EU tariff burden of US$81.5 billion highlights the severe economic risks facing Europe’s largest economy. According to a new analysis by Investors Observer, the prospect of blanket 50% tariffs on all EU goods exported to the United States has become “very realistic,” threatening to change trade relationships.

The report, based on 2024 export data from the UN Comtrade Database, reveals that Germany’s vulnerability stems primarily from its robust automotive sector, which exported US$34.87 billion in vehicles to the US last year.

Automotive dominance, combined with significant machinery and pharmaceutical exports, positions Germany as the most exposed EU nation despite overall export growth of just 1.2% in 2024.

Ireland’s pharmaceutical sector bears heavy risk

Ireland faces the second-largest EU tariff burden at $52 billion, driven almost entirely by its pharmaceutical industry. The country exported US$50.32 billion in pharmaceutical products to the US in 2024, and as reporter Sam Bourgi notes in the analysis, “Home to major drug manufacturers, the country’s export reliance on a single high-value industry makes it especially sensitive to tariffs.”

Any disruption could significantly impact Ireland’s GDP, employment in the life sciences sector, and foreign direct investment that have made the country a European hub for pharmaceutical manufacturing.

Technology hardware under pressure

The technology sector faces particular scrutiny in the tariff analysis, with several EU countries showing significant exposure through electronics and machinery exports. Italy’s US$39.2 billion EU tariff burden includes substantial industrial machinery exports worth US$14.21 billion, while the Netherlands faces US$17.5 billion in potential tariffs despite a 6% contraction in US exports during 2024.

Sweden’s exposure illustrates the growing importance of automotive technology in transatlantic trade. The country’s US$9.25 billion tariff risk is “fueled by a strong automotive sector (US$4.29 billion), complemented by machinery and pharmaceutical exports,” according to the report.

As a key player in sustainable manufacturing and clean technologies, Sweden’s vulnerability demonstrates how green tech initiatives have become intertwined with traditional trade relationships.

Smaller nations find shelter in service economies

While major manufacturing economies face substantial risks, smaller EU nations with service-oriented economies show minimal exposure to potential tariffs. Cyprus faces potential tariffs of just $0.03 billion, while Malta’s burden reaches $0.11 billion.

Smaller nations benefit from having a limited industrial sector and focus primarily on electronics exports that represent smaller absolute values. The analysis reveals that Luxembourg, with $0.36 billion in potential tariffs, benefits from only 41.7% of its exports being classified as “unspecified commodities,” which complicates tariff applicability and reduces sector-specific risks.

Supply chain disruption risks mount

The concentration of the EU tariff burden among the top 10 countries – representing over 89% of the total EU tariff impact – highlights the interconnected nature of transatlantic technology and pharmaceutical supply chains.

The report warns that US companies in pharma or automotive “could face higher input costs and supply chain disruptions.”

Their vulnerability extends beyond direct trade relationships. Belgium’s pharmaceutical exports grew by over 250% between 2023 and 2024, creating new exposure to US trade policy risk just as the country became a more significant player in transatlantic pharmaceutical trade.

Economic retaliation scenarios emerge

The potential for retaliatory measures adds complexity to the trade situation. Analysis suggests that while US producers in competitive industries might benefit from reduced EU market involvement, “the broader economic impact could be negative for the US as well. Tariffs may provoke EU retaliation, potentially targeting US exports to Europe.”

Poland’s US$7.05 billion EU tariff burden, anchored in machinery exports worth US$4.05 billion, exemplifies how emerging manufacturing centres in the EU have become increasingly dependent on US demand. As the report notes, new tariffs threaten to “stall its export-driven growth model and could force reconfiguration of transatlantic production networks.”

Market uncertainty already impacting investment.

The uncertainty surrounding the July 9 deadline has already affected business confidence and investment decisions. The report emphasises that volatility in global markets could “further dampen business investment and consumer confidence in both regions.”

For technology companies and pharmaceutical manufacturers with significant EU exposure, the analysis recommends considering “the risks of higher costs, supply chain volatility, and possible retaliatory measures when making investment decisions in sectors with significant exposure to EU trade.”

The concentration of the EU tariff burden among major economies – with Germany, Ireland, and Italy accounting for 56.7% of total exposure – underscores how quickly established trade relationships could shift if negotiations fail to produce an agreement by the early July deadline.